South East Asia Pemetrexed Market Size & Outlook, 2025-2033


South East Asia Pemetrexed Market Insights

  • Based on Reed Intelligence findings, the South East Asia Pemetrexed Market reached USD 45.44 Million in 2024 and is estimated to attain USD 51.11 Million by 2033.
  • From 2026 to 2033, the South East Asia market is expected to grow at a steady CAGR of 1.29%.
  • Within the By Application category, Malignant Pleural Mesothelioma dominated in 2024 in terms of market size contribution.
  • Over the forecast period, Malignant Pleural Mesothelioma is forecasted to deliver the fastest growth, positioning it as the most lucrative By Application segment.

Other Key Findings


  • As of 2024, South East Asia held 1.94% of the global Pemetrexed Market size.
  • By 2033, United States is anticipated to capture the largest share of the global Pemetrexed Market.
  • In Asia Pacific, China is expected to lead the regional Pemetrexed Market size by 2033.
  • India will remain the fastest-growing market in Asia Pacific, reaching USD 94.95 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 45.44 Million
Market Size In 2033 USD 51.11 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.29% (2025-2033)
Segmnetation Covered
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends